Pfizer Inc. which can be found using ticker (PFE) have now 21 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between $70.73 and $30.18 and has a mean target at $38.67. Given that the stocks previous close was at $30.56 this indicates there is a potential upside of 26.5%. The day 50 moving average is $33.39 and the 200 moving average now moves to $37.92. The market cap for the company is 174.32B. The stock price is currently at: $30.88 USD
The potential market cap would be $220,579,736,329 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 8.21, revenue per share of $13.86 and a 7.63% return on assets.
Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operates through two segments: Biopharma and PC1. Biopharma is engaged in the science-based biopharmaceutical business. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. The Company’s primary care products include Eliquis, Nurtec ODT/Vydura and the Premarin family; the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac and Trumenba; Comirnaty, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Eucrisa/Staquis and Cibinqo; the Vyndaqel family, Oxbryta, BeneFIX and Genotropin, and Sulperazon, Medrol, Zavicefta, Zithromax, Vfend and Panzyga. Its oncology products include Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena and Braftovi.
